Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Sell
35
ETON Quote, Financials, Valuation and Earnings
Last price:
$15.47
Seasonality move
:
-5.41%
Day range:
$15.33 - $16.52
52-week range:
$11.09 - $23.00
Dividend yield:
0%
P/E ratio:
92.00x
P/S ratio:
5.87x
P/B ratio:
17.93x
Volume:
424.5K
Avg. volume:
233.4K
1-year change:
28.73%
Market cap:
$414.6M
Revenue:
$39M
EPS (TTM):
-$0.25
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ETON
Eton Pharmaceuticals, Inc.
|
$22.5M | $0.19 | 76.69% | 577.97% | $30.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
SMTI
Sanara MedTech, Inc.
|
$28.1M | -- | 5.59% | -- | $41.00 |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.21 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ETON
Eton Pharmaceuticals, Inc.
|
$15.46 | $30.00 | $414.6M | 92.00x | $0.00 | 0% | 5.87x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$19.16 | $0.85 | $2.4B | 32.19x | $0.80 | 0% | 37.23x |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $683.9K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
SMTI
Sanara MedTech, Inc.
|
$24.35 | $41.00 | $217.6M | -- | $0.00 | 0% | 2.05x |
|
TOVX
Theriva Biologics, Inc.
|
$0.21 | $7.00 | $7.2M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ETON
Eton Pharmaceuticals, Inc.
|
57.18% | 1.476 | 5.3% | 1.14x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | 0.905 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
SMTI
Sanara MedTech, Inc.
|
88.52% | 0.476 | 16.72% | 1.64x |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ETON
Eton Pharmaceuticals, Inc.
|
$7.9M | -$1.2M | -14.04% | -29.85% | -5.22% | $11.7M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
SMTI
Sanara MedTech, Inc.
|
$23.8M | $3M | -8.95% | -20.48% | 11.25% | $1.1M |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Eton Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ETON or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -8.58% compared to Eton Pharmaceuticals, Inc.'s net margin of -255.85%. Eton Pharmaceuticals, Inc.'s return on equity of -29.85% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital ETONEton Pharmaceuticals, Inc.34.98% -$0.07 $54M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About ETON or NBY?
Eton Pharmaceuticals, Inc. has a consensus price target of $30.00, signalling upside risk potential of 94.05%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -95.56%. Given that Eton Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Eton Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ETONEton Pharmaceuticals, Inc.3 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is ETON or NBY More Risky?
Eton Pharmaceuticals, Inc. has a beta of 1.176, which suggesting that the stock is 17.644% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock ETON or NBY?
Eton Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Eton Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ETON or NBY?
Eton Pharmaceuticals, Inc. quarterly revenues are $22.5M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Eton Pharmaceuticals, Inc.'s net income of -$1.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Eton Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.00x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 32.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals, Inc. is 5.87x versus 37.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ETONEton Pharmaceuticals, Inc.5.87x 92.00x $22.5M -$1.9M NBYNovaBay Pharmaceuticals, Inc.37.23x 32.19x $521K -$1.3M
-
Which has Higher Returns ETON or OGEN?
Oragenics, Inc. has a net margin of -8.58% compared to Eton Pharmaceuticals, Inc.'s net margin of --. Eton Pharmaceuticals, Inc.'s return on equity of -29.85% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital ETONEton Pharmaceuticals, Inc.34.98% -$0.07 $54M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About ETON or OGEN?
Eton Pharmaceuticals, Inc. has a consensus price target of $30.00, signalling upside risk potential of 94.05%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 140.65%. Given that Oragenics, Inc. has higher upside potential than Eton Pharmaceuticals, Inc., analysts believe Oragenics, Inc. is more attractive than Eton Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ETONEton Pharmaceuticals, Inc.3 0 0 OGENOragenics, Inc.1 0 0 -
Is ETON or OGEN More Risky?
Eton Pharmaceuticals, Inc. has a beta of 1.176, which suggesting that the stock is 17.644% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.
-
Which is a Better Dividend Stock ETON or OGEN?
Eton Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ETON or OGEN?
Eton Pharmaceuticals, Inc. quarterly revenues are $22.5M, which are larger than Oragenics, Inc. quarterly revenues of --. Eton Pharmaceuticals, Inc.'s net income of -$1.9M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Eton Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.00x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals, Inc. is 5.87x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ETONEton Pharmaceuticals, Inc.5.87x 92.00x $22.5M -$1.9M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns ETON or PTN?
Palatin Technologies has a net margin of -8.58% compared to Eton Pharmaceuticals, Inc.'s net margin of --. Eton Pharmaceuticals, Inc.'s return on equity of -29.85% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ETONEton Pharmaceuticals, Inc.34.98% -$0.07 $54M PTNPalatin Technologies-- -- -- -
What do Analysts Say About ETON or PTN?
Eton Pharmaceuticals, Inc. has a consensus price target of $30.00, signalling upside risk potential of 94.05%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Eton Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Eton Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ETONEton Pharmaceuticals, Inc.3 0 0 PTNPalatin Technologies0 0 0 -
Is ETON or PTN More Risky?
Eton Pharmaceuticals, Inc. has a beta of 1.176, which suggesting that the stock is 17.644% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock ETON or PTN?
Eton Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ETON or PTN?
Eton Pharmaceuticals, Inc. quarterly revenues are $22.5M, which are larger than Palatin Technologies quarterly revenues of --. Eton Pharmaceuticals, Inc.'s net income of -$1.9M is higher than Palatin Technologies's net income of --. Notably, Eton Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.00x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals, Inc. is 5.87x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ETONEton Pharmaceuticals, Inc.5.87x 92.00x $22.5M -$1.9M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns ETON or SMTI?
Sanara MedTech, Inc. has a net margin of -8.58% compared to Eton Pharmaceuticals, Inc.'s net margin of 3.17%. Eton Pharmaceuticals, Inc.'s return on equity of -29.85% beat Sanara MedTech, Inc.'s return on equity of -20.48%.
Company Gross Margin Earnings Per Share Invested Capital ETONEton Pharmaceuticals, Inc.34.98% -$0.07 $54M SMTISanara MedTech, Inc.90.56% -$3.52 $53.5M -
What do Analysts Say About ETON or SMTI?
Eton Pharmaceuticals, Inc. has a consensus price target of $30.00, signalling upside risk potential of 94.05%. On the other hand Sanara MedTech, Inc. has an analysts' consensus of $41.00 which suggests that it could grow by 68.38%. Given that Eton Pharmaceuticals, Inc. has higher upside potential than Sanara MedTech, Inc., analysts believe Eton Pharmaceuticals, Inc. is more attractive than Sanara MedTech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ETONEton Pharmaceuticals, Inc.3 0 0 SMTISanara MedTech, Inc.2 0 0 -
Is ETON or SMTI More Risky?
Eton Pharmaceuticals, Inc. has a beta of 1.176, which suggesting that the stock is 17.644% more volatile than S&P 500. In comparison Sanara MedTech, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.17%.
-
Which is a Better Dividend Stock ETON or SMTI?
Eton Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanara MedTech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sanara MedTech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ETON or SMTI?
Eton Pharmaceuticals, Inc. quarterly revenues are $22.5M, which are smaller than Sanara MedTech, Inc. quarterly revenues of $26.3M. Eton Pharmaceuticals, Inc.'s net income of -$1.9M is lower than Sanara MedTech, Inc.'s net income of $834.5K. Notably, Eton Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.00x while Sanara MedTech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals, Inc. is 5.87x versus 2.05x for Sanara MedTech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ETONEton Pharmaceuticals, Inc.5.87x 92.00x $22.5M -$1.9M SMTISanara MedTech, Inc.2.05x -- $26.3M $834.5K
-
Which has Higher Returns ETON or TOVX?
Theriva Biologics, Inc. has a net margin of -8.58% compared to Eton Pharmaceuticals, Inc.'s net margin of --. Eton Pharmaceuticals, Inc.'s return on equity of -29.85% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital ETONEton Pharmaceuticals, Inc.34.98% -$0.07 $54M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About ETON or TOVX?
Eton Pharmaceuticals, Inc. has a consensus price target of $30.00, signalling upside risk potential of 94.05%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3158.85%. Given that Theriva Biologics, Inc. has higher upside potential than Eton Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Eton Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ETONEton Pharmaceuticals, Inc.3 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is ETON or TOVX More Risky?
Eton Pharmaceuticals, Inc. has a beta of 1.176, which suggesting that the stock is 17.644% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock ETON or TOVX?
Eton Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ETON or TOVX?
Eton Pharmaceuticals, Inc. quarterly revenues are $22.5M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Eton Pharmaceuticals, Inc.'s net income of -$1.9M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Eton Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.00x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals, Inc. is 5.87x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ETONEton Pharmaceuticals, Inc.5.87x 92.00x $22.5M -$1.9M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
